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Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4
in 278 breast cancer patients
Abstract
INTRODUCTION: The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR
(epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares
a high degree of structural and functional homology. It constitutes a complex network, coupling various
extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and
cross-activation. The most famous family member is HER2, which is a target in Herceptin therapy in
metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of
gene amplification and resulting protein overexpression. The HER2-related HER receptors have been
shown to interact directly with HER2 receptors and thereby mutually affect their activity and subsequent
malignant growth potential. However, the clinical outcome with regard to total HER receptor state
remains largely unknown. METHODS: We investigated HER1-HER4, at both the DNA and the protein
level, using fluorescence in situ hybridisation (FISH) probes targeted to all four receptor loci and also
immunohistochemistry in tissue microarrays derived from 278 breast cancer patients. RESULTS: We
retrospectively found HER3 gene amplification with a univariate negative impact on disease-free
survival (hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p = 0.031), whereas HER4
amplification showed a positive trend in overall and disease-free survival. Protein expression revealed
no additional information. CONCLUSION: Overall, the simultaneous quantification of HER3 and
HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of
breast cancer patients by providing additional prognostic information. The continuation of explorative
and prospective studies on all HER receptors will be required for an evaluation of their potential use for
specific therapeutic targeting with respect to individualised therapy.
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Abstract
Introduction The HER (human EGFR related) family of receptor
tyrosine kinases (HER1/EGFR (epidermal growth factor
receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/
c-erbB4) shares a high degree of structural and functional
homology. It constitutes a complex network, coupling various
extracellular ligands to intracellular signal transduction pathways
resulting in receptor interaction and cross-activation. The most
famous family member is HER2, which is a target in Herceptin™
therapy in metastatic status and also in adjuvant therapy of
breast cancer in the event of dysregulation as a result of gene
amplification and resulting protein overexpression. The HER2-
related HER receptors have been shown to interact directly with
HER2 receptors and thereby mutually affect their activity and
subsequent malignant growth potential. However, the clinical
outcome with regard to total HER receptor state remains largely
unknown.
Methods We investigated HER1–HER4, at both the DNA and
the protein level, using fluorescence in situ hybridisation (FISH)
probes targeted to all four receptor loci and also
immunohistochemistry in tissue microarrays derived from 278
breast cancer patients.
Results We retrospectively found HER3 gene amplification
with a univariate negative impact on disease-free survival
(hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p =
0.031), whereas HER4 amplification showed a positive trend in
overall and disease-free survival. Protein expression revealed no
additional information.
Conclusion Overall, the simultaneous quantification of HER3
and HER4 receptor genes by means of FISH might enable the
rendering of a more precise stratification of breast cancer
patients by providing additional prognostic information. The
continuation of explorative and prospective studies on all HER
receptors will be required for an evaluation of their potential use
for specific therapeutic targeting with respect to individualised
therapy.
Introduction
Gene amplification of HER2 (HER2/neu, c-erbB2) receptor
tyrosine kinase (RTK) is found in 10 to 25% of invasive breast
carcinomas [1,2] and is associated with an unfavourable
impact on the course of disease and reduced responsiveness
to tamoxifen therapy, for example [3,4]. The HER2 receptor
has frequently been described as dominantly triggering
mitogenic signalling within the type 1 growth factor receptor
family. As a ligandless orphan receptor, HER2 preferentially
heterodimerises with its relatives [5,6] and thereby has an
important role in signal triggering and amplification. Its malig-
nant potential and its key role in enhanced cell proliferation,
carcinogenesis, tumour progression and metastasis havePage 1 of 13
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studies [7].
The overexpressed receptor protein is exploited as the thera-
peutic target for Herceptin™, known as the humanised mono-
clonal antibody trastuzumab, in metastatic breast cancer and
has recently proved useful in designing adjuvant treatment for
breast carcinoma [8]. Moreover, strong HER2 expression rep-
resents the decisive molecular basis for tumour therapy tar-
geted at the same receptor. However, a therapeutic benefit in
terms of tumour regression, prolongation of recurrence-free
survival and even overall survival [9] is found for about 50% of
patients [9-11] depending on previous therapies, antibody
resistance and combination with other chemotherapeutics
such as paclitaxel or docetaxel [12]. This observation reflects
the substantial insufficiency of using HER2 gene amplification
or HER2 protein overexpression to predict patient responsive-
ness to Herceptin.
Hence, the identification of clinicopathological and molecular
characteristics of breast cancer to enable more accurate prog-
nosis of the course of disease and prediction of therapy
response to antibodies or small enzyme-inhibiting molecules
[13-15], for example, is a continuing challenge in the field of
diagnostic pathology. To this end, the three additional mem-
bers of the HER (human EGFR related)–RTK family HER1
(epidermal growth factor receptor (EGFR), c-erbB1), HER3
(c-erbB3) and HER4 (c-erbB4) are of particular interest
because of their ability to interact directly with HER2 [16]. On
the basis of their common evolutionary origin these receptors
share a high degree of structural and functional homology,
which is the molecular basis for receptor interaction and
cross-activation [17]. Thus, HER-receptor activity and func-
tionality depend on one another and thus the impact on tumour
cell proliferation and growth is likely to be dependent on HER-
receptor coexpression and communication.
Several immunohistochemical studies have been undertaken
to elucidate the coexpression profile of HER receptors in
breast cancer, providing preliminary data on other HER recep-
tors besides HER2, which may have an impact on the course
of disease and therapy responsiveness in breast cancer
patients [18-20].
In this study we performed a four-target fluorescence in situ
hybridisation (FISH) analysis of the HER1, HER2, HER3 and
HER4 gene loci together with centromere quantification using
278 primary breast cancer samples compiled into a tissue
microarray (TMA). Additionally, we immunohistochemically
stained the receptor proteins and categorised staining inten-
sity in accordance with EGFR pharmDX™ and HercepTest™
scoring guidelines. Furthermore, the results were compared
with the Ki-67 proliferation index, a prognostic marker in early
breast cancer [21]. Our objective was to determine the poten-
tial association between HER1-HER4 gene amplification or
altered protein expression and outcome and course of dis-
ease, as well as with known clinicopathological breast cancer
prognosticators [22]. We addressed the question of whether
alteration in the HER1, HER3 or HER4 genes or their protein
products conveys any prognostic value that is complementary
to or independent of HER2 that would allow a more precise
rendering of breast cancer patients into subgroups with differ-
ent clinical outcomes based on HER-receptor analysis.
Our data indicate additional HER3 and HER4 prognostic
markers in breast cancer that should be prospectively
explored in further detail. The integration of HER3 and HER4
analysis into routine cancer diagnosis would provide valuable
additional information. Further descriptive and particularly
functional studies are required to understand their impact on
the course of disease at the molecular and cellular levels
[16,23] and will provide the basis for designing specific tar-
geted therapeutics in terms of individualised disease
management.
Materials and methods
This study was approved by the Institutional Review Board of
the University of Regensburg, Germany.
Breast tumour samples and patient characteristics
Formalin-fixed paraffin-embedded tissue blocks from 278
female patients with invasive lobular or ductal unilateral pri-
mary breast cancer (median age 55 years; range 25 to 82
years) were obtained from the archives of the Institute of
Pathology, Regensburg, Germany, and were derived from a
consecutive series of sporadic breast cancers. The patients
were not involved in any clinical trial. Clinical data were
acquired by the Tumour Centre Inc., Regensburg. All patients
underwent surgery between 1992 and 2002. The histopatho-
logical characteristics are listed in Table 1. The median follow-
up period was 125.6 months (95% confidence interval (CI)
120.3 to 131.0). A total of 106 (38.1%) patients died, and
136 (48.9%) had a recurrence of breast cancer.
Tissue microarray (TMA) construction
TMAs were prepared as described previously [24,25]. For
each tumour a representative tumour section was selected
from a haematoxylin/eosin-stained section of the donor block.
Core cylinders with a diameter of 1.5 mm each were punched
from this area with a thin-walled stainless steel tube and
deposited into a recipient paraffin block. TMA sections were
mounted on charged slides (SuperFrost™Plus; Menzel GmbH,
Braunschweig, Germany). Haematoxylin/eosin-stained TMA
sections were used for reference histology.
Fluorescence in situ hybridisation
FISH was performed on 5 μm sections of the TMAs with the
use of directly labelled DNA probes for HER1, HER2, HER3
and HER4 (ZytoVision Ltd., Bremerhaven, Germany). The
probes identified locus-specific sequences for both the genesPage 2 of 13
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entiate between gene amplification and polysomy of the
respective chromosome.
TMA sections were dewaxed for 40 minutes in an incubator at
72°C and twice for 10 minutes in xylene. After being rehy-
drated in a graded ethanol series and rinsed in distilled water,
slides were placed in 0.01 M sodium citrate and steamed for
40 minutes in a water bath. Cell structures were digested in
0.1% pepsin (Sigma, Munich, Germany) and 0.01 M HCl for
10 minutes at 37°C. After washing in 2 × SSC (1 × SSC
(standard saline citrate) is 150 mM sodium chloride and 15
mM sodium citrate, pH 7) and water, slides were dehydrated
in graded alcohols and air-dried. Respective DNA probe sets
(10 μl each) were applied to the TMA area of each section.
Sections were coverslipped and the edges were sealed with
rubber cement. For co-denaturation of the probe and target
DNA, slides were placed for 5 minutes on a hotplate pre-
heated to 73°C and than transferred overnight to a warmed
hybridisation chamber at 37°C. After hybridisation, the rubber
cement was removed and the slides were immersed succes-
sively in 4 × SSC plus 0.3% Igepal (Serva, Heidelberg, Ger-
many), 2 × SSC and 1 × SSC for 10 minutes at 50°C. The
slides were rinsed briefly in Millipore water and air-dried.
Nuclei were counterstained with anti-fading DAPI (4',6-dia-
midino-2-phenylindole) Vectashield (Vector Laboratories, Bur-
lingame, CA, USA) and were analysed by epifluorescence
microscopy.
Microscopy, fluorescence in situ hybridisation scoring 
and digital imaging
Slides were imaged with an Axio Imager Z.1 (Zeiss, Göttingen,
Germany) equipped with specific filter sets for DAPI fluores-
cence (excitation 365 ± 20 nm, emission 450 ± 25 nm; Zeiss),
green fluorescence (excitation 500 ± 10 nm, emission 535 ±
15 nm) and red fluorescence (excitation 545 ± 15 nm, emis-
sion 610 ± 35 nm; AHF, Tübingen, Germany). Fluorescence
images were obtained with a Plan-Apochromat lens (63×,
numerical aperture 1.4) and recorded with a CCD (charge-
coupled device) camera AxioCam MRm (Zeiss). The plug-in
module ApoTome™ enabled the taking of pseudoconfocal,
scattered out-of-focus light-free images using transmission
grids and corresponding algorithms. To exclude the loss of
FISH signals, three-dimensional z-stacks were generated.
Each colour was recorded and digitally processed (filtering
and contrast enhancement) using AxioVision 4.5 software
(Zeiss). Corresponding images were superimposed.
FISH scoring was performed by counting fluorescence signals
in 25 malignant, non-overlapping cell nuclei for each case by
two independent interpreters (AS, MB). The FISH ratio was
assessed as the number of genes proportional to the number
of centromeres.
Immunohistochemistry
Immunostaining with anti-HER-receptor antibodies and MIB-1
(anti-Ki-67) was performed on 5 μm sections of the TMAs and
applied in accordance with the manufacturer's instructions.
Table 2 shows the antibody-specific staining and scoring char-
acteristics. MIB-1 was regarded as positive when 30% or
more of the nuclei in the punched tissue were stained. Inter-
pretation was performed independently by two experienced
pathologists (SS, AH). Stably transfected mouse fibroblasts
proved specific immunostaining (Figure 1).
Statistical analyses
The primary outcome measure, overall survival, was calculated
as the time from the date of diagnosis to death from any cause
or the date on which the patient was last known to be alive.
Patients lost to follow-up were treated as censored cases on
the basis of the date they were last known to be alive. The sec-
ondary outcome measure was the disease-free survival, the
time from diagnosis to the date of tumour-related death. Two
outcome-orientated approaches were used to determine the
cut-off points for HER1–HER4 FISH with regard to overall sur-
vival. First, we examined plots of the martingale residuals
against the single HER1–HER4 FISH variables using the
PROC LOESS option in SAS and chose DIRECT SMOOTH
with a smoothing parameter of 2/3. Second, we applied the
Contal and O'Quigley method [26], which is based on the log
Table 1
Patient age and histopathological characteristics of 278 breast 
carcinomas
Characteristic Number of patients
Node-positive, 
pN1–3
Node-negative, 
pN0
pNx
n = 131 n = 137 n = 10
pT
pT1 32 64 3
pT2 56 66 4
pT3 14 3 1
pT4 29 1 2
pTx - 3 -
Histological grade
G1 14 22 3
G2 52 75 5
G3 69 36 2
Gx - 4 -
ER status
0 26 26 5
1–12 79 72 5
ERx 26 39 -
The median age of patients was 55 years (range 25 to 82 years).Page 3 of 13
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multiple potential cut-off points. The cut-off points obtained
were then used to divide patients into two groups: amplified
and non-amplified. Survival curves were generated by using
the Kaplan–Meier method, and log-rank tests compared the
distributions between groups. In addition, hazard ratios (HR
values) with 95% CIs were estimated for a single covariate
(treated as continuous, and where appropriate as a dichoto-
mous variable) using the Cox proportional-hazards model.
Finally, multivariate Cox models were fitted to assess the prog-
nostic significance of HER1, HER3 and HER4 irrespective of
HER2. For cut-off point determination an adjusted 10% level
of significance was used. In all other analyses, p ≤ 0.05 (two-
Figure 1
Anti-HER-immunostaining of mouse fibroblasts, stably transfected with HER1, HER2, HER3 or HER4. Chinese hamster ovary wild-type, Jurkat and 
the three additional transfected fibroblast cell lines served as negative controls (magnification of slide overview ×16, magnification of cutout ×400, 
small circle indicates magnified area).
Table 2
Characteristics for anti-HER and anti-Ki-67 immunostaining and scoring
Characteristic HER1 HER2 HER3 HER4 Ki-67
Antibody Mouse mAb Rabbit pAb Mouse mAb Rabbit mAb Mouse mAb
Origin Dako Dako NanoTools Cell Signaling Dako
Clone 2–18C9 - 5A12 83B10 MIB-1
Concentration of 
primary antibody
EGFR pharmDX HercepTest (2.5 μg/
ml)
5 μg/ml culture 
supernatant
0.7 μg/ml 1.6 μg/ml
Staining pattern Membrane Membrane Cytoplasm and 
membrane
Cytoplasm and 
membrane
Nucleus
Epitope retrieval Proteinase K Heat induced, 10 mM 
citric acid buffer, pH 
6.0
Heat induced, 10 mM 
citric acid buffer, pH 
7.3
Heat induced, 10 mM 
sodium-citric acid pH 
6.0
Heat induced, 10 mM 
citric acid buffer, pH 
7.2
Blocking Endogenous 
peroxidase blocking
Endogenous 
peroxidase blocking
Endogenous 
peroxidase blocking
Endogenous 
peroxidase blocking
Endogenous 
peroxidase blocking
Primary antibody Overnight, 4°C Overnight, 4°C Overnight, 4°C Overnight, 4°C 30 min, room 
temperature
Detection system EnVision™ Dual Link 
System (Dako); DAB 
+ chromogenic 
substrate
EnVision™ Dual Link 
System (Dako); DAB 
+ chromogenic 
substrate
EnVision™ Dual Link 
System (Dako); DAB 
+ chromogenic 
substrate
EnVision™ Dual Link 
System (Dako); DAB 
+ chromogenic 
substrate
iVIEW™ DAB 
Detection Kit 
(Ventana)
Scoring in 
accordance with
EGFR pharmDx 
guidelines
HercepTest 
guidelines
EGFR pharmDx 
guidelines
EGFR pharmDx 
guidelines
Manufacturer's 
guidelines
mAb, monoclonal antibody; pAb, polyclonal antibody; DAB, diaminobenzidine; EGFR, epidermal growth factor receptor.Page 4 of 13
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performed with SPSS version 13.0 and SAS version 9.1 soft-
ware (SAS Institute, Cary, NC, USA). For cut-off point deter-
mination an SAS macro provided by Mandrekar and
colleagues [27,28] was applied.
Results
Microarrays of paraffin-embedded breast cancer tissue from
278 patients were used to analyse gene amplification and pro-
tein expression of each member of the HER family. Further-
more, we analysed tumour and nodal status and tumour
grading (Table 3) to indicate the representativeness of our
patient collective (p < 0.001).
Fluorescence in situ hybridisation
Newly designed probes for dual-colour FISH (courtesy of
ZytoVision Ltd., Bremerhaven, Germany) were established to
detect the gene and the centromere status of each receptor
(Figure 2).
The ratio distributions of HER1–HER4 FISH are presented in
Figure 3. Whereas HER2 ratios varied from 0.5 to 11.3, the
study population was more homogeneous with regard to
HER3 (range 0.5 to 2.3) and HER4 (range 0.6 to 1.5) and
extremely homogeneous with regard to HER1 (range 0.7 to
6.2). Thus, not only the range but also the number of different
ratios was restricted (HER2, 46; HER1, HER3 and HER4, 10
to 17). For HER1, these findings resulted in an accumulation
Table 3
Cox proportional hazards analysis for overall and disease-free survival
Technique Parameter Overall survival Disease-free survival
HR 95% CI p HR 95% CI p
FISH HER1
Continuous 0.1 1.02 0.97–1.07 0.380 1.03 0.98–1.07 0.301
Continuous 1.0 1.24 0.77–2.00 1.28 0.80–2.03
HER2
Continuous 0.1 1.02 1.01–1.02 0.001 1.02 1.01–1.03 <0.001
Continuous 1.0 1.16 1.06–1.26 1.18 1.08–1.29
Dichotomous (≤1.5 vs. ≥1.6) 2.07 1.33–3.21 0.001 2.33 1.48–3.68 <0.001
HER3
Continuous 0.1 1.07 0.99–1.15 1.09 1.01–1.18 0.031
Continuous 1.0 1.88 0.88–4.01 0.102 2.35 1.08–5.11
HER4
Continuous 0.1 0.90 0.75–1.09 0.289 0.92 0.76–1.12 0.395
Continuous 1.0 0.36 0.06–2.36 0.43 0.06–3.03
IHC HER1 1.66 0.96–2.86 0.070 1.55 0.87–2.77 0.139
HER2 1.42 0.90–2.25 0.131 1.58 0.99–2.54 0.057
HER3 0.84 0.51–1.37 0.484 0.93 0.55–1.56 0.778
HER4 1.48 0.97–2.26 0.070 1.51 0.97–2.33 0.066
HER2 divided 1.72 1.07–2.75 0.024 1.89 1.16–3.08 0.010
Ki-67 1.49 0.87–2.55 0.145 1.44 0.83–2.49 0.197
ER 0.58 0.37–0.91 0.018 0.59 0.37–0.96 0.031
PR 0.48 0.27–0.74 0.002 0.42 0.24–0.71 0.001
Histology pT 1.62 1.35–1.93 <0.001 1.72 1.43–2.08 <0.001
pN 1.98 1.67–2.35 <0.001 2.18 1.81–2.62 <0.001
Grading 2.10 1.54–2.87 <0.001 2.18 1.56–3.05 <0.001
Hazard ratios (HR), confidence intervals and p values of investigated parameters dependent on overall and disease-free survival (CI, confidence 
interval with lower and upper limits). All immunohistochemical and histological parameters were used as categorical variables. FISH, fluorescence 
in situ hybridisation; IHC, immunohistochemistry.Page 5 of 13
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percentage compared with its receptor relatives (HER2,
59.3%; HER3, 28.1%; HER4, 77.7%).
With overall survival as the primary outcome measure, the
plots of the martingale residuals versus HER1–HER4 FISH
(Figure 4) implied the interpretation of HER1, HER3 and
HER4 as continuous variables rather than dichotomising the
Figure 2
Anti-HER1–HER4 FISH in breast cancer tissue of one patient (dual probes). HER1: red cen 7, green loc 7p11 (diploid); HER2: red cen 17, green 
loc 17q12 (amplified); HER3: green cen 12, red loc 12q13 (moderately amplified); HER4: green cen 2, red loc 2q33 (diploid); 4',6-diamidino-2-
phenylindole core staining blue. Cen, centromere; loc, gene locus.
Figure 3
Distribution of HER1–4 FISH ratios. (a) Boxplots of HER1–HER4 FISH ratios (gene/centromere). (b) Magnified extract of (a) to demonstrate the 
different distribution pattern of ratios for each HER-family member.Page 6 of 13
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curve for HER2 FISH was roughly zero up to about 1.5 and
then increased rapidly. HER2 FISH was therefore converted
into a categorical variable. The results from the Contal and
O'Quigley method were consistent with the results from the
graphical approach. For HER2 FISH there were 46 distinct
values, any of which could be defined as a potential cut-off
point. The most informative value of the log rank statistic
occurred at the HER2 FISH ratio of 1.5 (adjusted p = 0.086).
This suggests that the cut-off point obtained is related to over-
all survival. The patients were therefore divided into two
groups: patients with HER2 FISH ratios of 1.5 or less, and
patients with HER2 FISH ratios of at least 1.6. Using the Con-
tal and O'Quigley method for HER1, HER3 and HER4 FISH,
again no cut-off point related to overall survival could be
defined (adjusted p > 0.33). Consequently, in further analyses
HER1, HER3 and HER4 FISH were included as continuous
variables, whereas HER2 FISH was assessed as both contin-
uous and dichotomous variables.
The HER2 gene was amplified in most cases without evidence
of polysomy, whereas both HER3 and HER4 gene alterations
were usually found in combination with polysomic gene status.
This finding partly explains lower FISH ratios for HER1 and, in
particular, for HER3 and HER4 compared with HER2.
FISH-dichotomised HER2 results are presented in Table 4.
HER2 showed 19.9% (46 of 231) positive cases and 80.1%
(185 of 231) negative cases. HR values for continuous distri-
bution of HER1–HER4 ratios for single (1.0) and one-tenth
(0.1) units are given in Table 3. The HR displays either the
increase (HR > 1.0) or the decrease (HR < 1.0) of the risk of
mortality by an enlargement of HER1–HER4 FISH ratio. A HR
value (single unit, 1.0) of 1.16 means that a patient with a
HER2 FISH ratio of 3.0, for example, has a 1.16-fold higher
risk (based on overall survival) than a patient with a ratio of 2.0.
Of 46 amplified cases, 40 (87.0%) also overexpressed HER2
protein. A correlation analysis of HER2 FISH and immunohis-
tochemistry (IHC; both dichotomous) was positive (p < 0.001;
Figure 4
Martingale residuals, plotted against HER1–HER4 FISH ratios, based on overall survival. FISH, fluorescence in situ hybridisation.Page 7 of 13
(page number not for citation purposes)
Breast Cancer Research    Vol 10 No 1    Sassen et al.correlation coefficient (CC) = 0.809). Reviewing the connec-
tion between HER3 FISH (continuous) and IHC (dichoto-
mous), we found a significant weak correlation (p = 0.038, CC
= 0.162) as well as for HER1 FISH and IHC (p = 0.010, CC
= 0.200). HER4 FISH and IHC data showed no correlation (p
= 0.327, CC = -0.075).
Patients with HER2 amplified breast cancer presented a sig-
nificantly worse outcome for overall (HER2 dichotomised: HR
= 2.07 (95% CI 1.33 to 3.21), p = 0.001; HER2 continuous:
HR = 1.16 (95% CI 1.06 to 1.26), p = 0.001) and disease-
free survival than patients with the non-amplified gene (Table
3 and Figure 5a2).
In addition, HER3-positive cases had a shorter disease-free
survival (HR = 2.35 (95% CI 1.08 to 5.11), p = 0.031). Ampli-
fication of HER1 caused a negative trend for survival (HR =
1.24 (95% CI 0.77 to 2.00), p = 0.380), whereas HER4
resulted in a decrease in the HR (HR = 0.36 (95% CI 0.06 to
2.36), p = 0.289). For a comparison of overall and disease-
free survival values see Table 3.
After performing univariate analysis based on overall survival,
we calculated an individual HR for each patient (HRind = exp
[BHERx × HERx continuous]) and plotted against the respec-
tive receptor gene HER1 to HER4 (Figure 6). In this analysis,
HER1, HER2 and HER3 displayed an increasing HR with
raised FISH ratios (continuous), whereas the HER4 HR
declined. HER3 had the steepest curve, followed by HER1
and HER2 as next steepest.
Exploring the effects of HER1, HER3 and HER4 in coexpres-
sion with HER2, HER2 results were separated into amplified
and non-amplified cases (Figure 7). In a multivariate approach,
dichotomised HER2 and continuous HER1, HER3 or HER4
were analysed. No significant interaction between HER2 and
each of its three relatives was found. Thus, for each patient the
individual HR without interaction was calculated (HRind = exp
[BHER2 × HER2 dichotomised + BHERx × HERx continuous]).
Amplified HER2 curves extend beyond non-amplified curves in
every case, showing the greater impact of HER2 in multivari-
ate Cox regression, visualised by adjusted HER2 HR values
(Figure 7). HER1, HER3 and HER4 have additional relevance
on the basis of increasing FISH ratio, given that the curves do
not run parallel to the x-axis. Whereas the upper graph dis-
plays the impact of HER2 amplification dependent on increas-
ing supplemental aberration of a second receptor, the lower
curve demonstrates the exclusive impact of this receptor gene
irrespective of HER2.
Figure 7 suggests that the main effects are additive in nature.
Figure 7a,b shows the same monotonically increasing trend:
higher HER1 and HER3 values were associated with higher
risk of mortality. This was valid for patients both with and with-
out HER2 gene amplification. In contrast, Figure 7c (HER4)
showed a monotonically decreasing trend: higher HER4 val-
ues were associated with a lower risk of mortality applied to
both the HER2 amplified and the HER2 non-amplified patient
group.
Immunohistochemistry
Immunostaining of all four HER receptors was performed (Fig-
ure 1). The specificity of applied antibodies was proved by
staining stably transfected mouse fibroblasts (NIH 3T3, kindly
provided by Roche Diagnostics, Penzberg, Germany).
For IHC, 14.5% (26 of 178) were identified as HER1 positive
(score 1+, 2+ and 3+), and 85.5% (152 of 178) as negative
(Table 4). In 22.4% (48 of 214) HER2 was overexpressed
(score 2+ and 3+), and 77.6% (166 of 214) were normal. IHC
of HER3 resulted in 75.1% (130 of 173) positive (score 1+,
2+ and 3+) and 24.9% (43 of 173) negative patients. For
HER4, 37.2% (71 of 191) of cases presented overexpression
(score 1+, 2+ and 3+), whereas 62.8% (120 of 191) did not.
Table 4
Results of fluorescence in situ hybridisation (HER2) and immunohistochemical staining (HER1–HER4)
FISH Immunohistochemistry
HER2 HER1 HER2 HER3 HER4
Evaluation characteristics n = 231 n = 178 n = 214 n = 173 n = 191
0 n.r. 152 (85.4) 112 (52.4) 43 (24.9) 120 (62.8)
1+ n.r. 7 (3.9) 54 (25.2) 115 (66.5) 49 (25.7)
2+ n.r. 11 (6.2) 26 (12.1) 14 (8.1) 17 (8.9)
3+ n.r. 8 (4.5) 22 (10.3) 1 0.5) 5 (2.6)
Positive 46 (19.9) 26 (14.5) 48 (22.4) 130 (75.1) 71 (37.2)
Negative 185 (80.1) 152 (85.5) 166 (77.6) 43 (24.9) 120 (62.8)
Numbers in parentheses are percentages. The total sample size was n = 278. Results in bold define data considered positive for 
immunohistochemistry. FISH, fluorescence in situ hybridisation; n.r. = non-relevant for FISH; cut-off point for HER2 FISH analysis (≤1.5 vs. ≥1.6) 
distinguishes amplified (positive) or normal (negative) gene status.Page 8 of 13
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with decreased overall survival (p = 0.129; HR = 1.42 (95%
CI 0.90 to 2.25), p = 0.131), a well established observation
that became unambiguously evident in cases that were scored
IHC 2+ and HER2 FISH positive (Figure 5a3; p = 0.022; HR
= 1.72 (95% CI 1.07 to 2.75), p = 0.024). A comparison of
positive and negative HER3 cases (Figure 5c) did not yield any
supplemental information (p = 0.483; HR = 0.84 (95% CI
0.51 to 1.37), p = 0.484). Immunostaining of HER1 (Figure
5b) indicated a negative effect for patients with overexpressed
levels (p = 0.067; HR = 1.66 (95% CI 0.96 to 2.86), p =
0.070). In addition, HER4 protein overexpression (Figure 5d)
tended to have a negative impact on disease (p = 0.068; HR
= 1.48 (95% CI 0.97 to 2.26), p = 0.070).
To examine the proliferation status in our patient cohort we
assessed Ki-67 IHC. In 24% of cases (36 of 150) we
documented a positive staining (more than 30% of nuclei) with
a negative effect on overall survival, whereas 76% of cases
(114 of 150) showed less or no staining resulting in a more
favourable outcome (p = 0.142; HR = 1.49 (95% CI 0.87 to
2.55), p = 0.145).
Discussion
Because screening of HER2 aberration as a prerequisite for
Herceptin therapy [29-31] enables the prediction of neither
the course of disease nor the individual response, the
identification of additional prognostic and predictive
parameters is of the utmost interest, primarily being those with
immediate impact on HER2. Further investigation of the
additional three, highly homologous HER2 cognate members
Figure 5
Kaplan–Meier curves of dichotomised variables, based on overall survivali t i  ri l , s  on overal  survival. Anti-HER1–HER4 immunohistochemistry (a1,b,c,d), anti-HER2 FISH (a2) 
and immunohistochemistry score 2+, stratified by FISH-amplified and non-amplified cases (a3). FISH, fluorescence in situ hybridisation.
Figure 6
Univariate analysis of HER1–HER4 FISH. Comparison of individually 
calculated hazard ratios (overall survival, HRind = exp [BHERx × HERx 
continuous]), based on the hazard ratio in one-tenth intervals showing 
the rising or declining hazard level as a function of increasing fluores-
cence in situ hybridisation (FISH) ratio.Page 9 of 13
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founded. Here we present first-hand data of a four-target FISH
and IHC analysis comprising all HER receptors in breast car-
cinomas by using TMA. The aim of this study was to identify
HER2-related molecules with additional prognostic signifi-
cance within the HER family.
We verified the known negative impact of HER2 amplification
on the overall and disease-free survival of patients. The dis-
crepancy of 13% of the patients showing amplification of the
HER2 gene but not overexpression of the HER2 protein is
consistent with the expected loss of IHC sensitivity associated
with tissue fixation and embedding [33]. The positive correla-
tion between HER2 FISH and HER2 IHC analysis is in accord-
ance with the literature (up to 95% concordance between
FISH and IHC) [2,6] as well as our own previous data (100%
concordance between FISH and fluorescent IHC) [34].
Similar to our FISH and IHC analysis, Tsutsui and colleagues
[19] found the combination of HER1 and HER2 expression in
breast cancer to have a severe negative impact on disease
outcome compared with normal protein levels, whereas the
prognostic value of HER2 overexpression seemed more pro-
nounced than HER1 overexpression. However, Diermeier and
colleagues [16] provided evidence that the HER1 expression
level in the breast cancer cell line SK-BR-3, coexpressed with
overexpressed HER2, has a key role in mediating the anti-pro-
liferative effect of Herceptin. Overall, HER1 gene amplification
or HER1 protein overexpression in this study was found to be
a rare event.
In contrast, the data presented in this study provide striking
evidence for a significance of alterations in HER3 in breast
cancer. This observation is supported by Holbro and col-
leagues [35], who identified the function of the HER2/HER3
dimer as an oncogenic unit in which HER3 couples active
HER2 to the downstream signalling phosphoinositide 3-
kinase/protein kinase B pathway. Blocking HER2 resulted in
antiproliferative effects accompanied by a decrease in HER3
signalling activity [36]. Although HER3 has no intrinsic kinase
activity to initiate the signalling process, ligand-bound or even
ligand-independent HER3 may form heterodimers with HER2
that are potent signalling complexes [37,38]. According to Liu
and colleagues [39], HER3 also contributes to HER2-associ-
ated tamoxifen resistance, and a decrease in HER3 levels
restores sensitivity to tamoxifen. Jones and colleagues [40]
provided a quantitative protein interaction network by applying
protein microarrays comprising virtually every Src homology 2
(SH2) and phosphotyrosine-binding (PTB) domain encoded in
the human genome. They found a difference in the extent to
which the HER receptors form protein–protein interactions
when overexpressed, and consequently found the HER2–
HER3 complex to have the most pronounced promiscuity with
regard to activate intracellular signalling. Our results indicate
the significance of the HER2/HER3 aberration in the
increasing HR and therefore risk of mortality after multivariate
analysis of HER2 and HER3 (Figure 7).
We detected a positive impact of HER4 on disease outcome
with FISH but not with IHC analysis, as reflected by the lack of
correlation between FISH and IHC data. HER4 protein overex-
pression has previously been described as a positive prognos-
tic factor, a suggestion based on investigative approaches
Figure 7
Multivariate analysis of dichotomised HER2 FISH with continuous HER1, HER3 or HER4 FISHi i  I  it  continuous ER1, HER3 or HER4 FISH. Individually calculated hazard ratios (overall survival, 
HRind = EXP [BHER2 × HER2 dichotomised + BHERx × HERx continuous]) for HER1 (a), HER3 (b) and HER4 (c) fluorescence in situ hybridisation, 
divided into HER2 amplified (ratio ≥ 1.6; filled circles) and HER2 non-amplified (ratio ≤ 1.5; open circles) patients.Page 10 of 13
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uted to growth controlling and differentiation signalling.
Barnes and colleagues [43] showed that HER4 decreases
HER2 signalling activity by leading to decreased proliferation
activity and increased apoptosis. In accordance with these
data, we were also able to show via FISH analysis a HER2-
compensating effect of HER4 represented by a decreased
HER2 HR in the presence of alteration of HER4 (Figure 7).
Furthermore, in support of a potential impact of HER4 amplifi-
cation on improved outcome, we found that HER4 amplifica-
tion detected by FISH was correlated with a positive
oestrogen receptor status (p = 0.001, CC = 0.266)
[18,44,45]. Significant correlation of HER4 positivity with low
bromodeoxyuridine-derived proliferation indices as described
by Tovey and colleagues [18] is associated with a good prog-
nosis in breast cancer tumours. Contrary conclusions were
reported by Vogt and colleagues [46], who found that HER4
amplification and ER activity were negatively correlated. These
differences may occur as a result of the variable responses by
HER4 to its activating ligand Heregulin, resulting in either pro-
liferation or differentiation, and perhaps influenced by
homodimerisation or heterodimerisation with other HER-family
members [47].
Vidal and colleagues considered that the HER4 cell-killing
intracellular domain 4ICD might be responsible for association
with overall improved patient prognosis [48] by accumulating
in mitochondria, causing an efflux of cytochrome c and result-
ing in mitochondrion-regulated apoptosis [49]. It is known that
HER-receptor activity and signalling is variable and depends
on a particular receptor coexpression profile, potentially
explaining the unequivocally strong correlation between HER4
alteration/overexpression and tumour grade or proliferation
index [50]. To discover a potential relationship between the
proliferation index and HER4 FISH-associated positive or
HER4 IHC-associated negative patient outcome, we per-
formed Ki-67 immunostaining. Positive MIB-1 IHC resulted in
a negative trend (overall survival) in a univariate analysis, which
is consistent with the literature [21]. In fact, Her4 IHC and Ki-
67 were positively correlated (p = 0.002, CC = 0.256),
whereas no correlation was found between HER4 FISH and
Ki-67 (p = 0.267, CC = -0.095). Detailed functional studies
addressing the impact of HER4 in the context of well-
described coexpression patterns will elucidate the importance
of HER4 within the HER-receptor family.
Information on HER1, HER3 and HER4 protein overexpres-
sion is extremely variable in the literature [20,44,51]; for exam-
ple 16 to 36% for HER1, 18 to 26% for HER3 and 12 to 82%
for HER4, but is usually similar for HER2 (23 to 27%). Our
data fell within these ranges, except for HER3 IHC results
(75%). With regard to a HER2 coexpression profile, 18.4% of
cases additionally overexpressed HER1, 85.0% HER3 and
71.4% HER4. Although the protein statuses of HER2 and
HER3 (p = 0.013, CC = 0.197) and HER2 and HER4 (p <
0.001, CC = 0.446) were significantly correlated with one
another, no such correlation was found between HER2 and
HER1 IHC (p = 0.654, CC = 0.035), an observation sup-
ported by the results of Hudelist and colleagues [41].
Overall, the quality of immunohistochemical studies seems to
be highly inconsistent because of several factors such as indi-
vidual tissue preparation, the application of different detection
antibodies with different binding specificity, and user-depend-
ent interpretation of staining pattern and intensity [52]. Hence,
as demonstrated for HER2, in contrast to FISH, IHC is most
probably the less reliable tool for discriminating patients on the
basis of alterations in HER receptors [33,53]. Particularly with
regard to HER3 and HER4, numerous antibodies are commer-
cially available from which we could prove only one to be spe-
cific for each receptor (Figure 1). Furthermore, HER-receptor
overexpression can change during breast cancer develop-
ment, and both a decrease and an increase in expression have
been observed [42,], additionally challenging the interpreta-
tion of staining results.
In addition, the prognostic value of HER-family mRNA expres-
sion has been a matter of controversy. Bieche and colleagues
[55], using real-time quantitative RT-PCR in patients with
known long-term survival, found HER1 to be underexpressed
in 82.3% of cases, HER2 (16.9%) and HER3 (46.2%) to over-
expressed and HER4 both underexpressed (29.2%) and over-
expressed (24.6%). Among patients with high HER4 mRNA
levels, a shorter recurrence-free survival was found, suggest-
ing that HER4 mRNA status might reflect a marker of poor out-
come. However, Zaczek and colleagues [56] recently linked
HER4 amplification (differential-display PCR) to favourable
characteristics, as well as higher levels of HER3. RNA–RNA
in situ hybridisation might clarify any discrepancy between
gene and protein states and might fill an information gap.
Further subdivision of the patient cohort into subgroups with
regard to individual patient treatment or additional clinical
parameters was not considered in the study presented here
but should be investigated in a larger patient cohort to examine
the predictive value of HER1 to HER4.
Conclusion
FISH with hybridisation probes targeted to all genes encoding
HER receptors turned out to be a sensitive and reliable tool for
detecting potential alterations in breast cancer. Although the
dominant importance of HER2 over other HER receptors is
globally accepted [19], we were able to show a substantial
impact of HER3 amplification on outcome of breast cancer
disease (disease-free survival) even at low amplification rates.
Our data provide initial evidence for the integration of HER3
as well as HER4 analysis into the diagnosis of breast cancer.
Investigations are currently under way to determine the clinical
importance of individual but interrelated alterations in HER in
breast cancer at both the gene and protein levels. An inte-Page 11 of 13
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alterations may enable optimised patient stratification with
respect to disease outcome. The quantification of the acti-
vated receptor relative to the unactivated protein is a promis-
ing approach, particularly with regard to therapeutic response.
Further descriptive and functional studies of HER receptors
will serve to characterise the disease in terms of a given
molecular HER-receptor equivalent, thus providing an essen-
tial basis for individualised therapy.
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